AnaptysBio - Home
About
Overview
Strategy
Management
Board of Directors
Therapeutic Advisory Board
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Etokimab
ANB019
Checkpoint Agonists
Partnerships
Investors / News
Overview
News
Events
Goverance
Stock Information
Analyst Coverage
SEC Filings
FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Contact
Toggle
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
September 24, 2018
AnaptysBio Reports Positive Topline Data from Phase 2a Proof-of-Concept Clinical Trial of Etokimab in Severe Eosinophilic Asthma
AnaptysBio Reports Positive Topline Data from Phase 2a Proof-of-Concept Clinical Trial of Etokimab in Severe Eosinophilic Asthma
August 7, 2018
AnaptysBio Announces Second Quarter 2018 Financial Results and Provides Pipeline Updates
AnaptysBio Announces Second Quarter 2018 Financial Results and Provides Pipeline Updates
About
Technology
Pipeline
Investors
Careers
